Inclusion Criteria:

• Healthy adult males or female aged between 18 and 50 years.
• Body mass index within the range 19-29.9 kilograms/metre2
• Forced Expiratory Volume in 1 second (FEV1) >80% predicted and a FEV1/ Forced Vital Capacity (FVC) ratio > 0.7
• The subject has an increase in sGAW of >% over pre-dose baseline within 2 h of administration of 400 ug salbutamol by MDI inhaler at screening or in the 3 months before screening.
• subject has an increase in sGaw of ?25% over pre-dose baseline within 2 h following 40 ug ipratropium bromide at screening or in the 3 months before screening
• subjects are current non-smokers who have not used any tobacco products in the 6-month period preceding the screening visit and have a pack history of < 10 pack years.

Exclusion criteria:

• who have a past or present disease, which as judged by the Investigator and medical monitor may affect the outcome of the study or the safety of the subject
• history of respiratory disease
• significant abnormal 12 lead ECG, QTc(B) and QTc(F) value at screening >450msec on an individual ECG or a PR interval outside the range 120-210 msec
• supine mean heart rate outside the range 45-90 beats per minute (bpm) at screening.
• subject has donated a unit of blood within the 56 days or intends to donate within 56 days after completing the study
• subject is currently taking regular (or course of) medication whether prescribed or not (with the exception of contraceptives, including vitamins and herbal remedies such as St John's Wort.
• subject has participated in a clinical study with a New Chemical Entity (NCE) within the past 1 month
• infected with the Hepatitis B, Hepatitis C, or HIV virus
• subject has a history of drug or other allergy, which, in the opinion of the Investigator, contraindicates their participation